Cargando…

Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer

The purpose was to explore potential biomarkers of the efficacy and toxicity of triple therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer (MBC). Tumor tissues before treatment and blood samples at pretreatment, during and after treatment were col...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ozaki, Yukinori, Tsurutani, Junji, Mukohara, Toru, Iwasa, Tsutomu, Takahashi, Masato, Tanabe, Yuko, Kawabata, Hidetaka, Masuda, Norikazu, Futamura, Manabu, Minami, Hironobu, Matsumoto, Koji, Yoshimura, Kenichi, Kitano, Shigehisa, Takano, Toshimi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475259/ https://www.ncbi.nlm.nih.gov/pubmed/36118297 http://dx.doi.org/10.1016/j.dib.2022.108558

Ejemplares similares

Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
por: Masuda, Jun, et al.
Publicado: (2023)

Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report
por: Ozaki, Yukinori, et al.
Publicado: (2017)

Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study
por: Ozaki, Yukinori, et al.
Publicado: (2018)

Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B)
por: Masuda, Hiroko, et al.
Publicado: (2023)

Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B)
por: Sakai, Hitomi, et al.
Publicado: (2023)

Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
por: Takahashi, Momoko, et al.
Publicado: (2019)

Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
por: Masuda, Norikazu, et al.
Publicado: (2021)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer
por: Kosaka, Yoshimasa, et al.
Publicado: (2022)

Mitigation of paclitaxel-induced peripheral neuropathy in breast cancer patients using limb-cooling apparatus: a study protocol for a randomized controlled trial
por: Funasaka, Chikako, et al.
Publicado: (2023)

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients
por: Tanabe, Yuko, et al.
Publicado: (2020)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

The efficacy and safety of paclitaxel plus bevacizumab therapy in breast cancer patients with visceral crisis
por: Funasaka, Chikako, et al.
Publicado: (2021)

Effectiveness of self-help workbook intervention on quality of life in cancer patients receiving chemotherapy: results of a randomized controlled trial
por: Takano, Toshimi, et al.
Publicado: (2021)

Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
por: Nakayama, Yoshie, et al.
Publicado: (2013)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
por: Iwasa, Tsutomu, et al.
Publicado: (2019)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
por: Kimbara, Shiro, et al.
Publicado: (2018)

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
por: Tsurutani, Junji, et al.
Publicado: (2018)

Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study
por: Ozaki, Yukinori, et al.
Publicado: (2018)

Squamous cell carcinoma arising from a mature cystic teratoma of the ovary: Successful treatment with carboplatin, paclitaxel, and bevacizumab
por: Fukase, Mika, et al.
Publicado: (2020)

First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors
por: Iwasa, Satoru, et al.
Publicado: (2022)

Prospective observational study of the efficacy of nivolumab in Japanese patients with advanced melanoma (CREATIVE study)
por: Yamazaki, Naoya, et al.
Publicado: (2021)

Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports
por: Yoshino, Koji, et al.
Publicado: (2019)

Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
por: Nakamura, Yoshio, et al.
Publicado: (2016)

Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center
por: Ozaki, Yukinori, et al.
Publicado: (2021)

The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Phase I/II study of cisplatin combined with weekly paclitaxel in patients with advanced non-small-cell lung cancer
por: Yoshimura, N, et al.
Publicado: (2004)

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature
por: Song, Lei, et al.
Publicado: (2020)

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2015)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2020)

Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B)
por: Yokoe, Takamichi, et al.
Publicado: (2021)

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
por: Yamamoto, Yutaka, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer
por: Hagi, Takaomi, et al.
Publicado: (2020)

Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study
por: Matsuoka, Ayumu, et al.
Publicado: (2016)

Pharmacodynamic Modeling of the Entire Time Course of Leukopenia after a 3‐Hour Infusion of Paclitaxel
por: Minami, Hironobu, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_68oqj383l144pj8pc4thuqgk0h